Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its product candidates include PTG-100, which has first-in-class potential as an oral, a4b7 integrin-specific antagonist peptide for the treatment of inflammatory bowel disease (IBD); PTG-200, a gastrointestinal-restricted peptide product candidate for the treatment of IBD; and PTG-300, an injectable hepcidin mimetic peptide for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.
This stock was on a bad downward trajectory, but things turned around today: Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease
